Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Fournel

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
Revue Des Maladies Respiratoires|August 6, 2002
[Exercise test and evaluation of exertional dyspnoea in former coal miners]M N Favre, F Roche, B Januel, et al.
Public Health|February 5, 2017
Design and validation of a self-administered questionnaire as an aid to detection of occupational exposure to lung carcinogensC Pélissier, V Dutertre, P Fournel, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|June 1, 2007
MN/CA9: a potential gene marker for detection of malignant cells in effusionsG Li, K Passebosc-Faure, G Feng, et al.
Anti-Cancer Drugs|February 1, 1995
Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? The French Navoban Study GroupM Marty, J P Kleisbauer, P Fournel, et al.
Critical Reviews in Oncology/Hematology|August 3, 2007
An open multicenter phase II trial of docetaxel-gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage IIIB pleura/IV non-small-cell lung cancer (NSCLC): the GFPC 02-02a studyH LeCaer, P Fournel, H Jullian, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 27, 2006
Cost-minimization analysis of a phase III trial comparing concurrent versus sequential radiochemotherapy for locally advanced non-small-cell lung cancer (GFPC-GLOT 95-01)A Vergnenegre, C Combescure, P Fournel, et al.
Revue Des Maladies Respiratoires|January 1, 1986
[Technics for the exploration of pulmonary arteriovenous shunts in liver cirrhosis. Apropos of 2 cases]J M Vergnon, J F De Bonadona, J Riffat, et al.
Bulletin Du Cancer|January 1, 1992
[Comparison of 2 cisplatin and etoposide dosages in relapsing small cell lung cancer]V Trillet-Lenoir, C Lasset, D Arpin, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 1993
Limited disease small cell lung cancer: alternating combination of doxorubicin, etoposide, ifosfamide and hyperfractionated radiotherapy. Final results of a multicentric pilot study for the Groupe Lyonnias d'Oncologie Thoracique (GLOT)V Trillet-Lenoir, F Mornex, F Chauvin, et al.
International Journal of Radiation Oncology, Biology, Physics|July 1, 1990
Hyperfractionated radiotherapy alternating with multidrug chemotherapy in the treatment of limited small cell lung cancer (SCLC). Groupe Lyonnais d'Oncologie ThoraciqueF Mornex, V Trillet, F Chauvin, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
Revue Des Maladies Respiratoires|August 6, 2002
[Exercise test and evaluation of exertional dyspnoea in former coal miners]M N Favre, F Roche, B Januel, et al.
Public Health|February 5, 2017
Design and validation of a self-administered questionnaire as an aid to detection of occupational exposure to lung carcinogensC Pélissier, V Dutertre, P Fournel, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|June 1, 2007
MN/CA9: a potential gene marker for detection of malignant cells in effusionsG Li, K Passebosc-Faure, G Feng, et al.
Anti-Cancer Drugs|February 1, 1995
Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? The French Navoban Study GroupM Marty, J P Kleisbauer, P Fournel, et al.
Critical Reviews in Oncology/Hematology|August 3, 2007
An open multicenter phase II trial of docetaxel-gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage IIIB pleura/IV non-small-cell lung cancer (NSCLC): the GFPC 02-02a studyH LeCaer, P Fournel, H Jullian, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 27, 2006
Cost-minimization analysis of a phase III trial comparing concurrent versus sequential radiochemotherapy for locally advanced non-small-cell lung cancer (GFPC-GLOT 95-01)A Vergnenegre, C Combescure, P Fournel, et al.
Revue Des Maladies Respiratoires|January 1, 1986
[Technics for the exploration of pulmonary arteriovenous shunts in liver cirrhosis. Apropos of 2 cases]J M Vergnon, J F De Bonadona, J Riffat, et al.
Bulletin Du Cancer|January 1, 1992
[Comparison of 2 cisplatin and etoposide dosages in relapsing small cell lung cancer]V Trillet-Lenoir, C Lasset, D Arpin, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 1993
Limited disease small cell lung cancer: alternating combination of doxorubicin, etoposide, ifosfamide and hyperfractionated radiotherapy. Final results of a multicentric pilot study for the Groupe Lyonnias d'Oncologie Thoracique (GLOT)V Trillet-Lenoir, F Mornex, F Chauvin, et al.
International Journal of Radiation Oncology, Biology, Physics|July 1, 1990
Hyperfractionated radiotherapy alternating with multidrug chemotherapy in the treatment of limited small cell lung cancer (SCLC). Groupe Lyonnais d'Oncologie ThoraciqueF Mornex, V Trillet, F Chauvin, et al.
Pageof 9